Cancer Vaccine in Phase II Trial

10.12.2004

Hørsholm - Danish Pharmexa A/S will initiate the first phase II trial with its HER-2 Protein AutoVac™ breast cancer vaccine. The trial including up to 50 breast cancer patients will start in Hungary, followed by Poland within a few weeks, and is expected to be concluded by mid-2006. An additional phase II trial with the vaccine formulated in a stronger immuno-stimulatory adjuvant is under preparation to be concluded in late 2006. The vaccine has been designed to generate an antibody response against the HER-2 protein, over-expressed in many cancers including breast cancers.

Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...

Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...

Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...

Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...

Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...

Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...